ABN.AS: $40.75 ▲ 0.30 (0.74%)DSFIR.AS: $99.66 ▼ -0.99 (-0.98%)GMAB.CO: $2,487.00 ▲ 42.00 (1.72%)REP.MC: $29.21 ▼ -0.31 (-1.05%)SOON.SW: $267.80 ▲ 3.20 (1.21%)CRWD: $263.01 ▼ -12.03 (-4.37%)HPE: $70.30 ▼ -3.16 (-4.30%)AMD: $594.24 ▼ -13.86 (-2.28%)DELL: $576.47 ▼ -9.59 (-1.64%)PANW: $403.83 ▼ -14.95 (-3.57%)MRNA: $213.74 ▼ -11.26 (-5.00%)AAPL: $340.97 ▲ 4.33 (1.29%)AMZN: $259.53 ▼ -2.90 (-1.11%)MSFT: $541.15 ▲ 6.08 (1.14%)NVDA: $226.32 ▼ -2.96 (-1.29%)CIEN: $404.86 ▼ -44.91 (-9.99%)DDOG: $287.29 ▼ -5.97 (-2.04%)SNPS: $502.51 ▼ -7.48 (-1.47%)CAP.PA: $115.35 ▲ 0.30 (0.26%)TSCO.L: $511.00 ▲ 7.20 (1.43%)WKL.AS: $77.16 ▲ 2.16 (2.88%)

Company Details

Bluejay Diagnostics, Inc.

BJDX - NASDAQ

Identifiants & Marche

Ticker BJDX
ISIN US0956333019
CIK 0001704287
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Medical - Devices

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.